Lymph node metastasis as a favorable prognostic factor in metastatic urothelial carcinoma with histological variants treated with pembrolizumab: a retrospective multicentric study (YUSHIMA study-04)

Key Points

• To evaluate the role of lymph node metastasis as a prognostic factor in metastatic urothelial carcinoma patients treated with pembrolizumab.
• Retrospective analysis of patients with mUC
• Inclusion of patients treated with pembrolizumab
• Assessment of outcomes based on the presence of lymph node metastasis and histological variants
• Lymph node metastasis associated with improved outcomes
• Specific for patients with histological variants of urothelial carcinoma
• Provides evidence for its role as a favorable prognostic factor

Abstract